New combo therapy aims to improve multiple myeloma treatment
NCT ID NCT04091126
First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-phase study tests a new drug, belantamab mafodotin, added to standard medications (bortezomib, lenalidomide, dexamethasone) for adults newly diagnosed with multiple myeloma. About 118 participants will receive different schedules of the new drug to find the safest and most effective dose. The goal is to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Westwood, Kansas, 66205, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Newcastle, New South Wales, 2298, Australia
-
GSK Investigational Site
Clayton, Victoria, 3168, Australia
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Edmonton, Alberta, T6G 1Z2, Canada
-
GSK Investigational Site
London, Ontario, N6A 5W9, Canada
-
GSK Investigational Site
Poitiers, 86021, France
-
GSK Investigational Site
Dresden, 01307, Germany
-
GSK Investigational Site
Hamburg, 20246, Germany
-
GSK Investigational Site
Schwerin, 19049, Germany
-
GSK Investigational Site
Tübingen, 72076, Germany
-
GSK Investigational Site
Bologna, 40138, Italy
-
GSK Investigational Site
Meldola FC, 47014, Italy
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Poznan, 61-848, Poland
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 03722, South Korea
-
GSK Investigational Site
Seoul, 137-701, South Korea
-
GSK Investigational Site
Badalona, 08916, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Madrid, 28027, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
-
GSK Investigational Site
PamplonaNavarra, 31008, Spain
-
GSK Investigational Site
Pozuelo de AlarcOn Madr, 28223, Spain
-
GSK Investigational Site
Santander, 39008, Spain
-
GSK Investigational Site
Leicester, LE1 5WW, United Kingdom
-
GSK Investigational Site
Oxford, OX3 7LE, United Kingdom
-
GSK Investigational Site
Southampton, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.